Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 3 · 50%High 1 · 16.7%

LAMA vs placebo

Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg · adults and children with cystic fibrosis

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 770 participants
Moderate

LAMA vs placebo

Change in baseline trough FEV1 · adults and children with cystic fibrosis

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 772 participants
Moderate

LAMA vs placebo

Lung function: FEV1 mL (change from baseline) · adults and children with cystic fibrosis

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

LAMA vs placebo

Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 974 participants
Low

LAMA vs placebo

Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis

LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.04]
2 studies · 807 participants
High

LAMA vs placebo

Pulmonary exacerbations · adults and children with cystic fibrosis

LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
RR 0.6 [0.32, 1.12]
2 studies · 805 participants
Moderate